The FDA approved a supplemental application for Keytruda (pembrolizumab) on March 21, 2022. This approval, designated BLA 125514 S-110, was granted based on efficacy data. The sponsor for this application was Merck Sharp Dohme.
What this means
The supplemental FDA approval for Keytruda (pembrolizumab) on March 21, 2022, signifies an expansion of the drug's approved uses based on demonstrated efficacy. This type of approval is granted when a manufacturer submits additional data supporting the drug's effectiveness for a new indication, a different patient population, or a revised dosing regimen. While the specific details of the new indication are not provided in the current data, this approval means that the FDA has reviewed and accepted evidence that Keytruda is safe and effective for this new purpose. For clinicians, this expands the therapeutic options available for patients who may benefit from pembrolizumab, allowing for its use in a broader context than previously approved. Patient advocates can note that this represents a new opportunity for treatment, pending the release of specific indication details. Researchers may look for the underlying data that supported this efficacy claim to further understand the drug's mechanism and application.
Source
The information regarding this supplemental approval was obtained from the FDA's official records, specifically a document detailing the approval of supplemental application BLA 125514 S-110 for Keytruda (pembrolizumab). This record was accessed on March 21, 2022, via accessdata.fda.gov.